<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01487993</url>
  </required_header>
  <id_info>
    <org_study_id>Metformin 2011-6</org_study_id>
    <secondary_id>2010-023980-17</secondary_id>
    <nct_id>NCT01487993</nct_id>
  </id_info>
  <brief_title>Metformin in Obese Children and Adolescents</brief_title>
  <acronym>MetVoorMin</acronym>
  <official_title>An Efficacy, Safety and Pharmacokinetic Study on the Short-term and Long-term Use of Metformin in Obese Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jeroen Bosch Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether metformin is effective in reducing BMI and
      insulin resistance in obese children and adolescents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of obesity in children and adolescents is increasing rapidly and is associated
      with significant medical and psychosocial consequences persisting into adulthood.

      Obesity may lead to metabolic complications, such as insulin resistance, which can progress
      via impaired fasted glucose and impaired glucose tolerance to type 2 diabetes mellitus (T2DM)
      and to the development of micro- and macro-vascular complications.

      Metformin, an oral anti-diabetic licensed for T2DM for adults and children from 10 years
      onwards, is already used off label in obese children and adolescents with insulin resistance,
      even though the specific effects of metformin in these obese children and adolescents have
      not been elucidated, particularly upon long-term use.

      The rationale for this study is based on the hypothesis that metformin may reduce body mass
      index (BMI), insulin resistance and percentage of body-fat in obese children and adolescents
      with insulin resistance. Further more it is anticipated that metformin may delay the
      progression to T2DM and thereby micro- and macro-vascular complications in obese children and
      adolescents with insulin resistance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in BMI from baseline</measure>
    <time_frame>18 months and 36 months</time_frame>
    <description>Change in BMI after part 1 (double blind) and part 2 ( follow-up)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Insulin resistance from baseline</measure>
    <time_frame>3; 6; 9; 12; 15; 18; 24; 30 and 36 months</time_frame>
    <description>calculated by the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal and hepatic function</measure>
    <time_frame>3; 6; 9; 12; 15; 18; 24; 30 and 36 months</time_frame>
    <description>creatinine and alat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>3; 6; 9; 12; 15; 18; 24; 30 and 36 months</time_frame>
    <description>The amount of reported adverse effects, in relation to the achieved dose level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)-parameters: clearance (ml/min)</measure>
    <time_frame>9 months</time_frame>
    <description>Clearance where applicable expressed per body weight, age category, Tanner Stage and gender, clearance will be determined with a two-compartment pharmacokinetic model using non linear mixed effect modelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat percentage</measure>
    <time_frame>0, 9, 18 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical fitness</measure>
    <time_frame>0, 9, 18 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>0, 9, 18 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term efficacy</measure>
    <time_frame>36 months</time_frame>
    <description>Based on BMI and HOMA-IR values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term safety</measure>
    <time_frame>36 months</time_frame>
    <description>Renal and hepatic function after 36 months of metformin use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term tolerability</measure>
    <time_frame>36 months</time_frame>
    <description>The amount of adverse effects after 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular complications</measure>
    <time_frame>36 months</time_frame>
    <description>Measured as micro-albuminuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrovascular complications</measure>
    <time_frame>36 monthts</time_frame>
    <description>Measured with Pulse Wave Velocity and Augmentation Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of T2DM</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK-parameters: volume of distribution (liters)</measure>
    <time_frame>9 months</time_frame>
    <description>Volume of distribution, where applicable expressed per body weight, age category, Tanner Stage and gender, volume of distribution will be determined with a two-compartment pharmacokinetic model using non linear mixed effect modelling.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin with lifestyle intervention during 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and lifestyle intervention during 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle intervention</intervention_name>
    <description>Lifestyle intervention: 18 months physical therapy and dietary advice</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 10 and ≤ 16 years at study entry

          -  Caucasian descent

          -  Obesity defined as BMI-SDS &gt; 2.3

          -  Insulin resistance defined as HOMA-IR ≥ 3.4.

          -  An obtained informed consent from subjects and parents/caregivers.

        Exclusion Criteria:

          -  Presence of T2DM (American Diabetes Association criteria)

          -  Presence of endocrine disorders with steroid therapy

          -  Suspicion of polycystic ovarium syndrome;

          -  Height &lt; -1.3 SD of target height;

          -  Syndrome disorders with or without mental retardation;

          -  Use of anti-hyperglycaemic drugs;

          -  Pregnancy (pregnancy test will be performed, if applicable);

          -  (History of) alcohol abuse;

          -  Impaired renal and/or hepatic function (defined as GFR &lt; 80 ml/min. GFR=40 x length
             (cm) / serumcreatinin (μmol/l and ALAT &gt;150% of normal value for age);

          -  Use of ritonavir; use of ACE inhibitors;

          -  Insufficient knowledge of the Dutch language.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marja MJ van der Vorst, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>'s Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2011</study_first_submitted>
  <study_first_submitted_qc>December 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2011</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>Van der Vorst</investigator_full_name>
    <investigator_title>Mrs. M.M.J. van der Vorst, paediatrician-clinical pharmacologist</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Children</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Metformin</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

